IL13 and blepharoconjunctivitis: Although the underlying mechanism of blepharoconjunctivitis in AD patients is still not completely elucidated, some authors have suggested that the blockade of IL-4 and IL-13 may increase the activity of specific ligands, such as OX40 ligand, involved in atopic keratoconjunctivitis [31].